Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FDMT 4D Molecular Therapeutics	$4.10 -5.0%	$3.78	$2.24 ▼ $28.93	$189.72M	2.81	817,638 shs	196,317 shs
FENC Adherex Technologies	$8.69 +1.7%	$7.56	$3.96 ▼ $8.88	$239.71M	0.39	92,730 shs	80,323 shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A
TIL Instil Bio	$28.23 +18.6%	$23.19	$9.70 ▼ $92.00	$185.19M	2.15	190,990 shs	596,590 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FDMT 4D Molecular Therapeutics	0.00%	+6.64%	-5.86%	+54.53%	-80.64%
FENC Adherex Technologies	0.00%	+5.27%	+3.02%	+66.70%	+49.48%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TIL Instil Bio	0.00%	+22.90%	-14.17%	+103.39%	+185.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FDMT 4D Molecular Therapeutics	2.27 of 5 stars	3.3	2.0	0.0	0.0	2.3	1.7	0.6
FENC Adherex Technologies	1.7071 of 5 stars	3.6	1.0	0.0	0.0	0.0	3.3	0.0
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	2.6089 of 5 stars	3.5	2.0	0.0	0.0	1.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	621.75% Upside
FENC Adherex Technologies	3.25	Buy	$13.00	49.68% Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A
TIL Instil Bio	3.00	Buy	$119.00	321.54% Upside

Current Analyst Ratings Breakdown

Latest TCRR, TIL, FENC, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
6/5/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$125.00 ➝ $125.00
6/2/2025	TIL Instil Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/22/2025	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$110.00 ➝ $105.00
5/20/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
5/14/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $13.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FDMT 4D Molecular Therapeutics	$40K	4,743.03	N/A	N/A	$11.05 per share	0.37
FENC Adherex Technologies	$47.54M	5.04	$0.03 per share	272.48	($0.21) per share	-41.36
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$25.96 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.51	N/A	N/A	N/A	-45.52%	N/A	-26.37%	8/12/2025 (Estimated)
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A
TIL Instil Bio	-$74.14M	-$11.97	N/A	N/A	N/A	N/A	-45.52%	-29.23%	8/12/2025 (Estimated)

Latest TCRR, TIL, FENC, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FENC Adherex Technologies	-$0.12	-$0.04	+$0.08	-$0.04	$8.18 million	$8.51 million
5/13/2025	Q1 2025	TIL Instil Bio	-$2.02	-$4.32	-$2.30	-$4.32	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
FENC Adherex Technologies	N/A	5.13	4.97
TCRR TCR2 Therapeutics	N/A	2.96	2.96
TIL Instil Bio	0.58	30.33	30.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FDMT 4D Molecular Therapeutics	99.27%
FENC Adherex Technologies	55.51%
TCRR TCR2 Therapeutics	64.76%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
FDMT 4D Molecular Therapeutics	9.60%
FENC Adherex Technologies	10.98%
TCRR TCR2 Therapeutics	25.01%
TIL Instil Bio	46.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
FENC Adherex Technologies	10	27.60 million	24.57 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable
TIL Instil Bio	410	6.56 million	3.51 million	No Data

TCRR, TIL, FENC, and FDMT Headlines

Recent News About These Companies

US FDA clears Instil Bio’s IND application for AXN-2510, a PD-L1xVEGF bispecific antibody, for a phase 1 trial in relapsed/refractory solid tumours

July 4 at 5:41 AM | pharmabiz.comP

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

July 3, 2025 | manilatimes.netM

Instil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - Nasdaq

July 3, 2025 | nasdaq.com

Instil Bio stock jumps after FDA clearance of IND application

July 2, 2025 | in.investing.com

Instil Bio Shares Climb After FDA Clears Tumor Treatment Application

July 2, 2025 | marketwatch.com

Instil Bio Shares Surge on FDA Clearance for Investigational Cancer Therapy

July 2, 2025 | msn.com

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 2, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/02/3109003/0/en/instil-bio-announces-u-s-f-d-a-clearance-of-investigational-new-drug-ind-application-for-axn-2510-a-pd-l1xvegf-bispecific-antibody-for-a-phase-1-trial-in-relapsed-refractory-solid-.html$

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

June 20, 2025 | zacks.com

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet

June 16, 2025 | zacks.com

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

June 11, 2025 | globenewswire.com

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

June 4, 2025 | zacks.com

Instil Bio appoints new Chief Medical Officer

June 4, 2025 | uk.investing.com

Instil Bio appoints Jamie Freedman as Chief Medical Officer

June 2, 2025 | msn.com

Instil Bio, Inc. Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer to Propel Cancer Therapy Development

June 2, 2025 | quiverquant.comQ

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

June 2, 2025 | globenewswire.com

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025 | globenewswire.com

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

May 29, 2025 | zacks.com

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

May 29, 2025 | zacks.com

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025 | seekingalpha.com

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...

May 25, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
SoundHound’s AI Growth Story Is Just Getting Started
By Gabriel Osorio-Mazilli | June 16, 2025
View SoundHound’s AI Growth Story Is Just Getting Started
3 Stocks Set to Double—And There's Still Time to Buy
By Nathan Reiff | June 12, 2025
View 3 Stocks Set to Double—And There's Still Time to Buy
The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
By Jeffrey Neal Johnson | June 22, 2025
View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried World
GitLab: Buy It Low While You Still Can—Higher Prices Are Coming
By Thomas Hughes | June 11, 2025
View GitLab: Buy It Low While You Still Can—Higher Prices Are Coming

TCRR, TIL, FENC, and FDMT Company Descriptions

4D Molecular Therapeutics NASDAQ:FDMT

$4.10 -0.22 (-4.99%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$4.22 +0.13 (+3.17%)

As of 07/3/2025 04:47 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Adherex Technologies NASDAQ:FENC

$8.68 +0.15 (+1.70%)

As of 07/3/2025 03:12 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Instil Bio NASDAQ:TIL

$28.23 +4.42 (+18.56%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$28.23 0.00 (0.00%)

As of 07/3/2025 04:54 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time